Cladribine

Especificaciones

4291-63-8Número CAS

636-978-6Número CE

(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-olNombre IUPAC

C10H12ClN5O3Fórmula química

285.69 g/molPeso molecular

Cladribine; 4291-63-8; 2-Chloro-2'-deoxyadenosine; Leustatin; 2-Chlorodeoxyadenosine; 2-CdA; Chlorodeoxyadenosine; Litak; ADENOSINE, 2-CHLORO-2'-DEOXY-; CldAdo; 2-Chloro-2'-deoxy-beta-adenosine; cladribina; mavenclad; Cladaribine; cladribinum; Leustat; 2-chloro-deoxyadenosine; RWJ 26251; 2ClAdo; DTXSID8022828; RWJ-26251; (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; NSC-105014; 47M74X9YT5; 2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine; 2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine; DTXCID602828; CHEBI:567361; (2R,3S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; NSC105014; 2'-Deoxy-2-chloroadenosine; Leustatine; RefChem:388887; 2-Chloro-2-deoxyadenosine; L01BB04; L04AA40; NSC105014-F; MFCD00153939; MLS000028377; (2R,3S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol; Cladarabine; SMR000058553; Movectro; Mylinax; (2R,3S,5R)-5-(6-amino-2-chloro-purin-9-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol; Leustatin (TN); CL9; CAS-4291-63-8; 2 Chlorodeoxyadenosine; SR-01000003063; NSC 105014; BRN 0624220; UNII-47M74X9YT5; CCRIS 9374; Adenosine, 2-chloro-2'-deoxy; Cladribine CRS; HSDB 7564; Cladribine [USAN:USP:INN:BAN]; Mavenclad (TN); NCGC00018167-03; Cladribine (Standard); CLADRIBINE [MI]; RWJ-26251-000; CLADRIBINE [INN]; CLADRIBINE [JAN]; Opera_ID_1191; CLADRIBINE [HSDB]; CLADRIBINE [USAN]; CLADRIBINE [VANDF]; CLADRIBINE [MART.]; SCHEMBL3775; CHEMBL1619; CLADRIBINE [USP-RS]; CLADRIBINE [WHO-DD]; Cladribine (JAN/USP/INN); 2-chloro-2'-deoxy-adenosine; cid_20279; MLS000028484; MLS000759397; MLS001077345; MLS001424194; CLADRIBINE [EMA EPAR]; Cladribine - Bio-X trade mark; GTPL4799; orb1225068; orb1305319; 2-Chloro-2'-deoxy-D-adenosine; CLADRIBINE [ORANGE BOOK]; SCHEMBL29355473; BDBM38920; CLADRIBINE [EP MONOGRAPH]; CLADRIBINE [USP IMPURITY]; CLADRIBINE [USP MONOGRAPH]; GLXC-05407; HMS2052K13; HMS2232C23; HMS3715F17; Tox21_110834; Tox21_300596; EBC-11113; HY-13599R; NSC-05014; NSC-105014-F; AKOS015854898; AKOS015892544; Cladribine for peak identification CRS; AC-7591; CCG-101116; CS-2057; DB00242; NC00366; NC06337; NCGC00022567-05; NCGC00022567-06; NCGC00022567-07; NCGC00022567-08; NCGC00022567-09; NCGC00164384-01; NCGC00254518-01; 2-Chloro-2'-deoxyadenosine, antileukemic; AS-12366; BC164318; BP-25407; HY-13599; SY059947; C4402; NS00005088; SW197746-4; D01370; 9-(2-Deoxy-b-D-ribofuranosyl)-2-chloroadenine; AB00382963-17; AB00382963_19; F078689; Q414030; 2-Chloro-2 inverted exclamation mark -deoxyadenosine; SR-01000003063-7; BRD-K93034159-001-25-8; SR-01000003063-10; Cladribine, European Pharmacopoeia (EP) Reference Standard; 6-amino-2-chloro-9-(2-deoxy-beta-erythropentofuranosyl)purine; Cladribine, United States Pharmacopeia (USP) Reference Standard; 6-amino-2-chloro-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine; Cladribine for peak identification, European Pharmacopoeia (EP) Reference Standard; 24757-90-2Sinónimos